Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GO-2301
- Development stage
- Preclinical
- Lead developer
- General Oncology
- Modality
- Small Molecules
- Administration
- Intravitreal
01
Overview
GO-2301 is a small molecule therapeutic candidate developed by General Oncology. It is designed to bind irreversibly within the DNA helix, a mechanism that traps cells in the M phase of the cell cycle and induces terminal proliferation arrest. The drug is currently in the IND-enabling stage of development. Its primary indications include proliferative retinopathy, wet age-related macular degeneration (wet AMD), and diabetic retinopathy, as well as applications in oncology. By targeting the fundamental process of cell division, GO-2301 aims to address diseases characterized by pathological cellular proliferation.
- Other names
- GO-2301GO2301GO 2301
02
Targets
DNA
Beyond the preview
Go deeper on GO-2301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GO-2301.